Radius (RDUS) Enrols First Patient in Breast Cancer Study

A generic image of a line graph Credit: Shutterstock photo

Radius Health, Inc.RDUS announced that the first patient has been enroled in the phase I study on pipeline candidate, RAD140.

RAD140 is a nonsteroidal selective androgen receptor modulator (SARM) which is being evaluated for the treatment of hormone receptor positive breast cancer. The phase I trial is a safety and dose-ranging study in approximately 40 patients suffering from progressive metastatic or locally advanced or metastatic breast cancer. Postmenopausal women with metastatic hormone receptor positive breast cancer will receive escalating doses of RAD140 by oral administration over a period of 28 days in part A of the study. The primary safety outcomes include rate of dose-limiting toxicities, adverse events related to treatment and tolerability as measured by dose interruptions or adjustments. In addition, pharmacokinetics, pharmacodynamics and tumor response will also be evaluated.

The SARM mechanism of action is differentiated from both selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs). Consequently, RAD140 has significant potential to complement future applications of elacestrant (RAD1901) by targeting distinct mechanisms of endocrine resistance.

We note that an investigational new drug application submitted to the FDA for RAD140 has been accepted.

Radius' share price has increased 1.4% year to date compared with the industry's 4.6% gain.

In April the FDA approved Tymlos (abaloparatide-SC) for the treatment of postmenopausal women with high risk osteoporosis for fracture - defined as history of osteoporotic fracture - multiple risk factors for fracture, or patients who have failed or are intolerant to other osteoporosis therapies. Although the osteoporosis market in the United States holds great promise as approximately 1.4 million postmenopausal women suffer osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's LLY Forteo and Amgen Inc's AMGN Prolia. Moreover, the approved label carries a boxed warning of osteosarcoma (a malignant bone tumor). The company, however, suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues.

Meanwhile, Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women.

Zacks Rank & Key Pick

Radius Health currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Aduro Biotech ADRO , carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Aduro Biotech's loss per share estimates narrowed from $1.46 to $1.29 for 2017 and from $1.41 to $1.26 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report

Radius Health, Inc. (RDUS): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.